Chen's Journey with Zerpidio
See how the support of the people who love her helps Chen stay positive and determined as they face squamous small cell lung cancer together.
Juan Journey with Zerpidio
See how the support of the people who love her helps Chen stay positive and determined as they face squamous small cell lung cancer together.
More Patient Journey


Zerpidio can help
you fighting
Sq-NSCLC

What is the Squamous Non-Small Cell Lung Cancer ?
Lung cancer develops when cells in the lungs grow abnormally and uncontrollably, presenting a serious and potentially fatal health condition. This disease stands as a major global health burden, leading cancer-related deaths worldwide with GLOBOCAN 2020 data revealing approximately 1.8 million deaths (18% of all cancer mortality) in 2020.¹
Clinically, lung cancer is divided into two primary histological categories: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). These types are diagnosed based on how the cells look under a microscope.²
NSCLC is a diverse group of lung cancers classified by their cell types and appearance under a microscope. It consists of three main types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. ²
More Patients Live Longer
In a clinical trial of ZERPIDIO with chemotherapy (carboplatin and Nab-paclitaxel) that included 537 patients with locally advanced or metastatic squamous NSCLC lived longer with Zerpidio + chemotherapy.³
.png)
Sq-NSCLC : Squamous Non Small Cell Lung Cancer | OS : Overall Survival | PFS : Progressive Free Survival | HR : Hazard Ratio | nab-P/C: nab-Paclitaxel + CarboplatinSq-NSCLC : Squamous Non Small Cell Lung Cancer | OS : Overall Survival | PFS : Progressive Free Survival | HR : Hazard Ratio | nab-P/C: nab-Paclitaxel + Carboplatin
Zerpidio with chemotherapy as first-line treatment for locally advanced or metastatic squamous NSCLC reduced the risk of death by 27%³

Badan POM-Approved Indications
Serplulimab is approved by BPOM Indonesia for ES-SCLC and Sq-NSCLC
NMPA-Approved Indications
Serplulimab is approved by NMPA China for MSI-H solid tumors, Sq-NSCLC, ES-SCLC, and ESCC
EMA-Approved Indications
Serplulimab is approved by the European Medicines Agency (EMA) for ES-SCLC
FDA-Approved as orphan drug
Serplulimab approved by United States Food and Drug Administration (US FDA) as an orphan drug for ES-SCLC
Thai FDA-Approved Indications
Serplulimab is approved by Thai FDA for ES-SCLC and Sq-NSCLC
NPRA-Approved Indications
Serplulimab is approved by National Pharmaceutical Regulatory Agency (NPRA) for ES-SCLC
HSA SG-Approved Indications
Serplulimab is approved by Health Science Authority (HSA) for ES-SCLC
Tell your doctor if:
You have a history of :
Allergic reaction to other monoclonal antibody therapies
Kidney damage
Autoimmune disease
Organ transplant
Lung problems or breathing problems
Liver problems
You are pregnant or plan to become pregnant
You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.
Tell your doctor or nurse immediately if you have any signs or symptoms below:
Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;
Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;
Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;
Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;
Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;
Inflammation of the kidneys: decrease in the amount of urine you pass;
Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;
Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;
Inflammation of the eyes;
Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;
Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;
Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;
Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)
Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.
Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.
The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.
The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.
These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.
Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.
Important Safety Information
References
-
https://www.who.int/news-room/fact-sheets/detail/lung-cancer
-
Zhou C, Hu Y, Arkania E, et al. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell 2024;42:198-208.e3.
Badan POM-Approved Indications
Serplulimab is approved by BPOM Indonesia for ES-SCLC and Sq-NSCLC
NMPA-Approved Indications
Serplulimab is approved by NMPA China for MSI-H solid tumors, Sq-NSCLC, ES-SCLC, and ESCC
EMA-Approved Indications
Serplulimab is approved by the European Medicines Agency (EMA) for ES-SCLC
FDA-Approved as orphan drug
Serplulimab approved by United States Food and Drug Administration (US FDA) as an orphan drug for ES-SCLC
Thai FDA-Approved Indications
Serplulimab is approved by Thai FDA for ES-SCLC and Sq-NSCLC
NPRA-Approved Indications
Serplulimab is approved by National Pharmaceutical Regulatory Agency (NPRA) for ES-SCLC
HSA SG-Approved Indications
Serplulimab is approved by Health Science Authority (HSA) for ES-SCLC
Important Safety Information
Tell your doctor if:
You have a history of :
Allergic reaction to other monoclonal antibody therapies
Kidney damage
Autoimmune disease
Organ transplant
Lung problems or breathing problems
Liver problems
You are pregnant or plan to become pregnant
You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.
Tell your doctor or nurse immediately if you have any signs or symptoms below:
Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;
Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;
Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;
Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;
Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;
Inflammation of the kidneys: decrease in the amount of urine you pass;
Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;
Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;
Inflammation of the eyes;
Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;
Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;
Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;
Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)
Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.
Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.
The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.
The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.
These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.
Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.